EU won't take up option to buy more Astrazeneca vaccines
The EU has opted out of buying more vaccine doses from Astrazeneca and instead plans to buy vaccines from Pfizer/Biontech, since the latter company has better met the demands of its contract, and since its vaccine type has less severe side effects than those possibly connected with the Astrazeneca vaccine.
BY LOUISE WENDT JENSEN, TRANSLATED BY NIELSINE NIELSEN
The EU will not be making use of its contractual option to buy 100 million more vaccine doses from Astrazeneca, according to an EU spokesman for the EU Commission at a press conference in Bruxelles.
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.